Cerevel Therapeutics Holdings, Inc.

Cerevel Therapeutics Holdings, Inc.verified

CERE

Price:

$44.96

Market Cap:

$8.19B

Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. It is developing emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-concept trial in patients with drug-resistant focal onset seizures in epilepsy or focal epilepsy, as well as in phase 1 trial to treat acute anxiety. The company's products also comprise Tavapadon, a selective dopamine D1/D5 partial agonist that is in phase 3 clinical trial for the treatment of early- and late-stage Parkinson's disease; CVL-871, a sel...[Read more]

Industry

Biotechnology

IPO Date

2020-07-30

Stock Exchange

NASDAQ

Ticker

CERE

The Enterprise Value as of December 2024 (TTM) for Cerevel Therapeutics Holdings, Inc. (CERE) is 8.24B

According to Cerevel Therapeutics Holdings, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 8.24B. This represents a change of 40.50% compared to the average of 5.86B of the last 4 quarters.

Cerevel Therapeutics Holdings, Inc. (CERE) Historical Enterprise Value (quarterly & annually)

How has CERE Enterprise Value performed in the past?

The mean historical Enterprise Value of Cerevel Therapeutics Holdings, Inc. over the last ten years is 1.86B. The current 8.24B Enterprise Value has changed 44.18% with respect to the historical average. Over the past ten years (40 quarters), CERE's Enterprise Value was at its highest in in the February 2001 quarter at 1.52T. The Enterprise Value was at its lowest in in the June 2019 quarter at 0.

Quarterly (TTM)
Annual

Average

1.86B

Median

518.25M

Minimum

0

Maximum

6.36B

Cerevel Therapeutics Holdings, Inc. (CERE) Enterprise Value by Quarter and Year

Discovering the peaks and valleys of Cerevel Therapeutics Holdings, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Maximum Annual Increase = Infinity%

Maximum Annual Enterprise Value = 6.36B

Minimum Annual Increase = -100.00%

Minimum Annual Enterprise Value = 0

Quarterly (TTM)
Annual
YearEnterprise ValueChange
20236.36B27.19%
20225.00B17.08%
20214.27B390.74%
2020870.39M-40.45%
20191.46BInfinity%
20180-100.00%
2015165.75M-0.22%
2014166.10M3.30%
2013160.79M8.09%
2012148.76M26.28%

Cerevel Therapeutics Holdings, Inc. (CERE) Average Enterprise Value

How has CERE Enterprise Value performed in the past?

The current Enterprise Value of Cerevel Therapeutics Holdings, Inc. (CERE) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

3-year avg

5.21B

5-year avg

3.59B

10-year avg

1.86B

Cerevel Therapeutics Holdings, Inc. (CERE) Enterprise Value vs. Peers

How is CERE’s Enterprise Value compared to its peers?

Cerevel Therapeutics Holdings, Inc.’s Enterprise Value is greater than Avidity Biosciences, Inc. (3.41B), greater than Revolution Medicines, Inc. (7.90B), greater than Day One Biopharmaceuticals, Inc. (859.59M), greater than SpringWorks Therapeutics, Inc. (2.70B), greater than Ventyx Biosciences, Inc. (115.44M), greater than Nuvalent, Inc. (5.59B), greater than Travere Therapeutics, Inc. (1.86B), greater than Structure Therapeutics Inc. (1.47B), greater than Monte Rosa Therapeutics, Inc. (356.78M), greater than Design Therapeutics, Inc. (323.81M), greater than Werewolf Therapeutics, Inc. (-16084776.00), greater than Ikena Oncology, Inc. (43.80M), greater than Stoke Therapeutics, Inc. (467.23M), greater than Apellis Pharmaceuticals, Inc. (4.20B), greater than Terns Pharmaceuticals, Inc. (234.86M), greater than Blueprint Medicines Corporation (6.12B), greater than IGM Biosciences, Inc. (390.09M), greater than Cullinan Oncology, Inc. (591.52M), greater than Mineralys Therapeutics, Inc. (502.94M),

Build a custom stock screener for Cerevel Therapeutics Holdings, Inc. (CERE) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Cerevel Therapeutics Holdings, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Custom stock screener in Wisesheets

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Cerevel Therapeutics Holdings, Inc. (CERE) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Cerevel Therapeutics Holdings, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Custom stock templates in Wisesheets

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.

Frequently asked questions❓

What is the Enterprise Value?

How can you use the Enterprise Value?

What is Cerevel Therapeutics Holdings, Inc.'s Enterprise Value?

What is the highest Enterprise Value for Cerevel Therapeutics Holdings, Inc. (CERE)?

What is the 3-year average Enterprise Value for Cerevel Therapeutics Holdings, Inc. (CERE)?

What is the 5-year average Enterprise Value for Cerevel Therapeutics Holdings, Inc. (CERE)?

How does the current Enterprise Value for Cerevel Therapeutics Holdings, Inc. (CERE) compare to its historical average?